These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24554028)

  • 1. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Lima A; Seabra V; Martins S; Coelho A; Araújo A; Medeiros R
    Mol Biol Rep; 2014 May; 41(5):3349-57. PubMed ID: 24554028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
    Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients.
    Lima A; Seabra V; Bernardes M; Azevedo R; Sousa H; Medeiros R
    PLoS One; 2014; 9(10):e108165. PubMed ID: 25279663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Berrevoets M; den Hoed MAH; Zolk O; Hoerning S; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
    Pharmacogenet Genomics; 2018 Oct; 28(10):223-229. PubMed ID: 30222710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
    Arévalo E; Castañón E; López I; Salgado J; Collado V; Santisteban M; Rodríguez-Ruiz M; Martín P; Zubiri L; Patiño-García A; Rolfo C; Gil-Bazo I
    J Transl Med; 2014 Apr; 12():98. PubMed ID: 24726028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
    Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
    Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
    Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer.
    Takehara A; Kawakami K; Ohta N; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2005; 25(6C):4455-61. PubMed ID: 16334126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
    Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
    Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.
    Dong H; Bao D; Guo X; Hu J; Li X; Wan S; Xing J
    Tumour Biol; 2015 Sep; 36(9):7151-7. PubMed ID: 25877757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Fujita S; Masago K; Hatachi Y; Fukuhara A; Hata A; Kaji R; Kim YH; Mio T; Mishima M; Katakami N
    BMC Med Genet; 2010 Nov; 11():167. PubMed ID: 21114867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
    Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
    Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
    Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
    BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
    PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.